Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | CASP1 | P29466 | 1/20 | 0.49 |
| ▸ | AURKA | O14965 | 1/20 | 0.47 |
| ▸ | TTK | P33981 | 1/20 | 0.47 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.47 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.47 |
| ▸ | PIK3CA | P42336 | 8/20 | 0.40 |
| ▸ | MTOR | P42345 | 2/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | PIK3R1 | P27986 | 2/20 | 0.31 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.31 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.30 |
| ▸ | FEN1 | P39748 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL83967 | 0.83 | MAPT (0.50) | MAPTCASP1AURKATTKAURKB | |
| SCHEMBL24139835 | 0.80 | MAPT (0.51) | MAPTCASP1AURKATTKAURKB | |
| SCHEMBL12094605 | 0.79 | CRHR1 (0.34) | MAPTCASP1AURKATTKAURKB | |
| SCHEMBL12093567 | 0.78 | LMNA (0.38) | MAPTCASP1PIK3CACYP1A2CYP3A4 | |
| SCHEMBL112761 | 0.75 | MAPT (0.53) | MAPTCASP1AURKATTKAURKB | |
| SCHEMBL14060011 | 0.75 | MAPT (0.53) | MAPTCASP1AURKATTKAURKB | |
| SCHEMBL29540711 | 0.74 | MAPT (0.56) | MAPTCASP1AURKATTKAURKB | |
| SCHEMBL8986074 | 0.74 | MAPT (0.56) | MAPTCASP1AURKATTKAURKB | |
| SCHEMBL11775197 | 0.74 | HTT (0.37) | — | |
| Hydrochloric Acid SCHEMBL23501360 | 0.73 | MAPT (0.51) | MAPTCASP1AURKATTKAURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140170110-A1 | PYRIDIN-2(1H)-ONE DERIVATIVES USEFUL AS MEDICAMENTS FOR THE TREATMENT OF MYELOPROLIFERATIVE DISORDERS, TRANSPLANT REJECTION, IMMUNE-MEDIATED AND INFLAMMATORY DISEASES | ALMIRALL, S.A. (ES) | 2014-06-19 | — | — | US | disclosed |
| CN-103649085-A | Pyridin-2(1h)-one derivatives useful as medicaments for the treatment of myeloproliferative disorders, transplant rejection, immune-mediated and inflammatory diseases | ALMIRALL SA | 2014-03-19 | — | — | CN | disclosed |
| WO-2012160030-A1 | PYRIDIN-2 (1H) -ONE DERIVATIVES USEFUL AS MEDICAMENTS FOR THE TREATMENT OF MYELOPROLIFERATIVE DISORDERS, TRANSPLANT REJECTION, IMMUNE-MEDIATED AND INFLAMMATORY DISEASES | ALMIRALL, S.A. (ES) | 2012-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140170110-A1 | PYRIDIN-2(1H)-ONE DERIVATIVES USEFUL AS MEDICAMENTS FOR THE TREATMENT OF MYELOPROLIFERATIVE DISORDERS, TRANSPLANT REJECTION, IMMUNE-MEDIATED AND INFLAMMATORY DISEASES | JAK1, JAK3, JAK2 | MAPT 3564/4885CASP1 754/4885AURKA 1362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.